Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

Merck known as MSD outside of the United States and Canada, announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in...

To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

Precision AQ, a global commercialisation partner built to guide life science innovators through commercial complexity, announced the appointment of two new leaders who will accelerate the company's international growth and enhance delivery of...

A Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression.

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma...

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

KORU Medical Systems, Inc. a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, announced that the Company received...

China approves Libevitug, first-in-class therapy for hepatitis D

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated...

Align Technology Supports Children and Teens With 30 Invisalign® Treatments via Smiles4Canada Program

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative...

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. Tharmaratnam brings nearly three decades of...

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced positive results of an investigator-initiated...

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and...

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), announced the successful closing of its $23 million Series B financing led by S3 Ventures, with support from Intuitive Ventures, and a strategic...

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial...

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today...

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

Johnson & Johnson announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks. At Week 24, TREMFYA ®...

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

Asahi Kasei Corporation has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter, developed by its Asahi Kasei Bioprocess business unit. Designed...

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Inc. a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead Sciences, Inc. announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

PRM Pharma, LLC announces the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hypertension in adults. This milestone comes as the...

During FII Week in Riyadh, Rubedo Life Sciences and SVAX announce a strategic partnership

Rubedo Life Sciences, Inc. a leading AI-driven, clinical-stage biotech specializing in selective cellular rejuvenation medicines, announced a strategic partnership with SVAX during the Future Investment Initiative (FII) week in Riyadh. This...

Real-world data presented at TCT 2025 demonstrates that the EggNest™ Complete Radiation Protection System significantly reduces radiation exposure for the entire cath lab

At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg...

Baird Medical’s MWA system has achieved successful Medicare reimbursement at a prominent New York practice

Merck known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA®...